Erste Group Bank Brokers Increase Earnings Estimates for NVO

Novo Nordisk A/S (NYSE:NVO) – Investment analysts at Erste Group Bank raised their FY2027 earnings per share estimates for shares of Novo Nordisk A/S in a research note issued on Wednesday, July 15th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $3.20 per share for the year, up from their prior estimate of $3.18. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.38 per share.

Several other research firms have also weighed in on NVO. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday. Wolfe Research started coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $49.40 on Monday. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79. The firm has a fifty day moving average of $46.21 and a 200-day moving average of $45.77. The firm has a market capitalization of $220.58 billion, a P/E ratio of 11.60, a PEG ratio of 4.53 and a beta of 0.77. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion for the quarter.

Institutional Trading of Novo Nordisk A/S

Institutional investors have recently added to or reduced their stakes in the stock. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S during the 4th quarter worth $25,000. Scarborough Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at about $26,000. WealthCollab LLC raised its stake in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares in the last quarter. American National Bank & Trust bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $28,000. Finally, Maseco LLP bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $29,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk received a boost from continued momentum behind Wegovy, including reports that the newly approved oral version in Europe could expand the drug’s reach and improve the company’s competitive position. Wegovy Pill in Europe – Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug
• Positive Sentiment: Citi reportedly raised its price target on Novo Nordisk ahead of earnings, citing stronger-than-expected Wegovy pill launch trends and higher sales and profit estimates, which supports a more bullish near-term outlook. Citi lifts Novo Nordisk target on strong GLP-1 pill launch
• Positive Sentiment: Novo Nordisk also announced progress in China through Fangzhou’s launch of Kyinsu, a once-weekly basal insulin/GLP-1 combination therapy, broadening its international diabetes footprint. Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
• Neutral Sentiment: The company said it is continuing a DKK 15 billion share repurchase program, which can help offset dilution and signal management confidence, but is not a major new catalyst on its own. Novo Nordisk A/S – share repurchase programme
• Negative Sentiment: The biggest near-term headwind is Novo Nordisk’s lawsuit against Eli Lilly, alleging misleading advertising and outdated clinical data in campaigns for Zepbound and Mounjaro. While the suit aims to protect Novo’s brands, it also highlights intensifying competition in obesity drugs and adds litigation risk. Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.